TNFRSF17 and plasma cell myeloma: Until September 2022, there were already two anti-B cell maturation antigen (BCMA) CAR-T cell therapies that had been approved by the US FDA to treat adults with r/r multiple myeloma after four or more prior lines of therapy [16].